Skip to main content

Lonza manufactures coronavirus vaccine for Moderna

| News

Lonza manufactures coronavirus vaccine for Moderna


Lonza plans to start production of Moderna’s coronavirus vaccine in Switzerland before the end of the year. Moderna published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective. Moderna opened a subsidiary in Basel to drive forward the production of the vaccine from there.

Moderna is a vaccine manufacturer working on a COVID-19 vaccine. Based in Massachusetts, the manufacturer has founded a subsidiary in Basel. According to Basel Area Business & Innovation in August, Moderna was “vigorously supported” when setting up the new company, Moderna Switzerland GmbH. The support ranged from questions on setting up a company and work permits with regard to the COVID-19 situation to suggestions about office spaces. The successful establishment of a subsidiary by Moderna will highlight the attractiveness of the Basel area’s biotech ecosystem.

Lonza will manufacture the mRNA-1273 vaccine for Moderna. According to a press release from the Basel-based pharmaceutical supplier, large-scale production started at its American factory in Portsmouth, NH at the end of September. Production is also set to start at Lonza’s factory in Visp in the canton of Wallis before the end of the year. Lonza plans to manufacture 400 million vaccine doses per year at Visp. Back in May, Moderna and Lonza agreed on a total manufacturing output of 1 billion doses per year.

Moderna has recently published the initial results from a phase 3 study, according to which the vaccine candidate is 94.5 percent effective.

Lonza is also working on the development of a coronavirus vaccine with another American manufacturer: Humanigen. Cameron Durrant, CEO of Humanigen, is quoted in a press release on the collaboration, saying: “This collaboration with Lonza, a global manufacturing leader with expertise in technology transfer and an established track record of working with regulatory bodies for approved and commercialized products, comes at a crucial time to meet production demand for COVID-19 therapeutics this winter.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.